ASIA PACIFIC CRISPR MARKET FORECAST 2018-2026

ASIA PACIFIC CRISPR MARKET FORECAST 2018-2026

  • January 2018 •
  • 75 pages •
  • Report ID: 4595254
KEY FINDINGS
The revenue generated by the Asia-Pacific CRISPR market is expected to catapult from $92 million in 2017 to $1725 million by 2026, at a CAGR of 38.86%. CRISPR majorly finds its applications in industries like agriculture and animal breeding for this region.

MARKET INSIGHTS
China, Japan, and India are some of the major markets contributing to the Asia-Pacific CRISPR market. The Japanese CRISPR market contributed the highest revenue share in 2017, but it is the South Korea market that is expected to progress with the highest CAGR over the forecast period.

However, even though more and more research on GMOs is being performed in the Asia-Pacific region, people are still concerned about the undiscovered side effects and unanticipated adverse effects of the CRISPR technology on the environment. Also, possible misuse of CRISPR gene editing tools is another major factor hindering the market growth.

COMPETITIVE INSIGHTS
Intellia Therapeutics Inc, Caribou Biosciences Inc, Cellectis Bioresearch Sas, Integrated DNA Technologies (IDT), Crispr Therapeutics Ag,Genscript, Novartis International Ag, Editas Medicine, Transposagen Biopharmaceuticals Inc, Thermo Fisher Scientific, Sigma-Aldrich (Merck), Precision Biosciences and Horizon Discovery Plc are some of the established players in this market.
Country=APAC Date=201801 Topic=Forecast Publisher=InkwoodResearch Price=2000